In vitro and in vivo activity of antisense inhibitors of ras: Potential for clinical development

被引：0
|
作者：
Cowsert, LM
机构：
来源：
ANTI-CANCER DRUG DESIGN | 1997年 / 12卷 / 05期
关键词：
D O I：
暂无
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页码：359 / 371
页数：13
相关论文
共 50 条
  • [21] Neurofibromatosis type 1 tumour suppressor gene expression is deficient in psoriatic skin in vivo and in vitro:: a potential link to increased Ras activity
    Karvonen, SL
    Koivunen, J
    Nissinen, M
    Ylä-Outinen, H
    Björkstrand, AS
    Peltonen, J
    BRITISH JOURNAL OF DERMATOLOGY, 2004, 150 (02) : 211 - 219
  • [22] INHIBITION OF RAS FUNCTION IN-VITRO AND IN-VIVO USING INHIBITORS OF FARNESYL-PROTEIN TRANSFERASE
    KOHL, NE
    WILSON, FR
    THOMAS, TJ
    BOCK, RL
    MOSSER, SD
    OLIFF, A
    GIBBS, JB
    SMALL GTPASES AND THEIR REGULATORS, PT A, 1995, 255 : 378 - 386
  • [23] Development and Characterization of Selective FAK Inhibitors and PROTACs with In Vivo Activity
    Koide, Eriko
    Mohardt, Mikaela L.
    Doctor, Zainab M.
    Yang, Annan
    Hao, Mingfeng
    Donovan, Katherine A.
    Kuismi, Christina C.
    Nelson, Alissa J.
    Abell, Kathryn
    Aguiar, Mike
    Che, Jianwei
    Stokes, Matthew P.
    Zhang, Tinghu
    Aguirre, Andrew J.
    Fischer, Eric S.
    Gray, Nathanael S.
    Jiang, Baishan
    Nabet, Behnam
    CHEMBIOCHEM, 2023, 24 (19)
  • [24] The development of macrocyclic peptide Ras inhibitors
    Josephson, Kristopher
    Silvestri, Anthony
    Fribourgh, Jennifer L.
    Bray, Walter M.
    David, Brian
    Hanna, Cameron C.
    Chakka, Sai Kumar
    Hyatt, Alex
    Porcella, Monique
    Dieppa-Matos, Dio
    Pye, Cameron R.
    Schwochert, Joshua
    MOLECULAR CANCER RESEARCH, 2023, 21 (05)
  • [25] Current status of the development of Ras inhibitors
    Shima, Fumi
    Matsumoto, Shigeyuki
    Yoshikawa, Yoko
    Kawamura, Takashi
    Isa, Masayuki
    Kataokat, Tohru
    JOURNAL OF BIOCHEMISTRY, 2015, 158 (02): : 91 - 99
  • [26] The development and potential clinical utility of biomarkers for HDAC inhibitors
    Shi, Baowen
    Xu, Wenfang
    DRUG DISCOVERIES AND THERAPEUTICS, 2013, 7 (04): : 129 - 136
  • [27] An antisense platform for the pre-clinical development of novel LncRNA inhibitors in multiple myeloma
    Morelli, Eugenio
    Gulla, Annamaria
    Liu, Na
    Johnstone, Megan
    Vinaixa, Delaney
    Gramegna, Doriana
    Wen, Kenneth
    Tai, Yu-Tzu
    Chauhan, Dharminder
    Samur, Mehmet
    Shammas, Masood
    Fulciniti, Mariateresa
    Gryaznov, Sergei
    Anderson, Kenneth
    Munshi, Nikhil
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2022, 22 : S94 - S95
  • [28] The uptake of a fluorescently labelled antisense oligonucleotide in vitro and in vivo
    Robinson, ESJ
    Nutt, DJ
    Jackson, HC
    Hudson, AL
    JOURNAL OF NEUROSCIENCE METHODS, 2005, 147 (01) : 48 - 54
  • [29] Antisense oligonucleotides as inhibitors of genes that regulate AP-1: Pharmacology and clinical development
    Dean, NM
    McKay, RA
    Holmlund, J
    ANTISENSE & NUCLEIC ACID DRUG DEVELOPMENT, 1998, 8 (02): : 147 - 151
  • [30] The potential adverse effects of aromatase inhibitors on wound healing: in vitro and in vivo evidence
    Howgate, Daniel J.
    Gamie, Zakareya
    Panteliadis, Pavlos
    Bhalla, Amit
    Mantalaris, Athanasios
    Tsiridis, Eleftherios
    EXPERT OPINION ON DRUG SAFETY, 2009, 8 (05) : 523 - 535
12345